Listing 1 - 8 of 8 |
Sort by
|
Choose an application
Pancreatic Neoplasms --- Pancreas --- Receptors, Peptide --- Receptors, Gastrointestinal Hormone --- physiopathology --- metabolism --- metabolism --- metabolism
Choose an application
Geriatrics --- Gastroenterology --- Gastrointestinal hormones --- Gastrointestinal system --- Pediatric gastroenterology --- Child Nutrition --- Gastrointestinal Diseases --- Gastrointestinal Hormones --- Infant Nutrition --- Peptides --- Receptors, Gastrointestinal Hormone --- Congresses --- Diseases --- Endocrine aspects --- congresses --- in infancy & childhood --- physiology --- Physiology --- congresses. --- Congresses. --- Gastrointestinal hormones - Congresses. --- Pediatric gastroenterology - Congresses. --- Gastrointestinal system - Diseases - Endocrine aspects - Congresses.
Choose an application
Gastrointestinal Hormones. --- AIDS (Disease) --- -Acquired immune deficiency syndrome --- Acquired immunodeficiency syndrome --- Acquired immunological deficiency syndrome --- HIV infections --- Immunological deficiency syndromes --- Virus-induced immunosuppression --- Enteric Hormones --- Intestinal Hormones --- Hormones, Enteric --- Hormones, Gastrointestinal --- Hormones, Intestinal --- Intestinal Secretions --- Nursing --- Acquired Immunodeficiency Syndrome --- Nursing. --- nurses' instruction. --- -Nursing --- Nurses' instruction. --- Gastrointestinal Hormones --- Acquired immune deficiency syndrome --- Enteric Hormone --- Gastrointestinal Hormone --- Intestinal Hormone --- Hormone, Enteric --- Hormone, Gastrointestinal --- Hormone, Intestinal
Choose an application
The epidermal growth factor (EGF) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGFR therapies. Edited by John Haley and William J. Gullick, EGFR Signaling Networks in Cancer Therapy, is separated into two sections. The first of which probes the molecular pathways and the intersection of signaling networks which are frequently deregulated in human cancers, with a view to describing EGF receptor in a tumor tissue specific context. Meanwhile, the second section illustrates the many ways in which EGF receptor contribute to abnormal survival and migration signaling in cancer cells and to epithelial to mesenchymal transition and metastasis. The book also describes the mitogenic, survival, adhesive and migratory pathways within a framework of interacting subsystems that contribute to the activity and physiological regulation of the receptor in normal and neoplastic tissues. Even though there is still much to learn, this volume explores this fascinating system with compelling information.
Medicine & Public Health. --- Oncology. --- Cancer Research. --- Medicine. --- Médecine --- Cancérologie --- Cancer --Chemotherapy. --- Cancer --Treatment. --- Cancer --- Receptors, Gastrointestinal Hormone --- Receptor Protein-Tyrosine Kinases --- Cell Physiological Processes --- Diseases --- Receptors, Growth Factor --- Biochemical Processes --- Receptors, Cell Surface --- Cell Physiological Phenomena --- Biochemical Phenomena --- Receptors, Peptide --- Protein-Tyrosine Kinases --- Chemical Processes --- Chemical Phenomena --- Membrane Proteins --- Phenomena and Processes --- Protein Kinases --- Phosphotransferases (Alcohol Group Acceptor) --- Proteins --- Amino Acids, Peptides, and Proteins --- Phosphotransferases --- Chemicals and Drugs --- Transferases --- Enzymes --- Enzymes and Coenzymes --- Receptor, Epidermal Growth Factor --- Signal Transduction --- Neoplasms --- Medicine --- Health & Biological Sciences --- Oncology --- Treatment --- Chemotherapy --- Chemotherapy. --- Treatment. --- Cancer therapy --- Cancer treatment --- Therapy --- Cancer research. --- Tumors --- Cancer research --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Antineoplastic agents
Choose an application
The enormity of the literature on growth factors, plus the breadth of the biological disciplines and technical expertise required prohibits a comprehensive review by even a multi-disciplinary panel of authors. To provide an alternative that is feasible for authors and digestible by readers, this review compendium consists of a collection of articles, each covering an aspect of teh ErbB/EGF field. This compilation features articles on growth factor ligands, neuregulins, and individual receptors. The second part of the book concentrates on the biological context of the ErbB receptors, particular
Epidermal growth factor. --- Neoplasms. --- Receptor, Epidermal Growth Factor. --- Tumors. --- Receptors, Growth Factor --- Diseases --- Receptor Protein-Tyrosine Kinases --- Receptors, Gastrointestinal Hormone --- Protein-Tyrosine Kinases --- Receptors, Peptide --- Receptors, Cell Surface --- Protein Kinases --- Membrane Proteins --- Proteins --- Phosphotransferases (Alcohol Group Acceptor) --- Phosphotransferases --- Amino Acids, Peptides, and Proteins --- Chemicals and Drugs --- Transferases --- Enzymes --- Enzymes and Coenzymes --- Receptor, Epidermal Growth Factor --- Neoplasms --- Medicine --- Health & Biological Sciences --- Oncology --- Tumors --- Epidermal growth factor --- Growth. --- Receptors. --- Anthelone --- EGF (Growth factor) --- EGF-URO (Growth factor) --- EGF-Urogastrone --- Epidermal growth factor-Urogastrone --- Uroanthelone --- Uroenterone --- Cancer --- Neoplasm growth --- Tumor growth --- Growth --- Growth factors
Choose an application
The gastrointestinal tract (GIT) can be broadly divided into several regions: the stomach, the small intestine (which is subdivided to duodenum, jejunum, and ileum), and the colon. The conditions and environment in each of these segments, and even within the segment, are dependent on many factors, e.g., the surrounding pH, fluid composition, transporters expression, metabolic enzymes activity, tight junction resistance, different morphology along the GIT, variable intestinal mucosal cell differentiation, changes in drug concentration (in cases of carrier-mediated transport), thickness and types of mucus, and resident microflora. Each of these variables, alone or in combination with others, can fundamentally alter the solubility/dissolution, the intestinal permeability, and the overall absorption of various drugs. This is the underlying mechanistic basis of regional-dependent intestinal drug absorption, which has led to many attempts to deliver drugs to specific regions throughout the GIT, aiming to optimize drug absorption, bioavailability, pharmacokinetics, and/or pharmacodynamics. In the book "Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation" we aim to highlight the current progress and to provide an overview of the latest developments in the field of regional-dependent intestinal drug absorption and delivery, as well as pointing out the unmet needs of the field.
Medicine --- Pharmaceutical industries --- bioequivalence --- Biopharmaceutics Classification System --- in vitro --- dissolution test --- pravastatin --- oral absorption --- in silico modeling --- GastroPlus --- Phoenix WinNonlin --- pharmacokinetics --- clinical studies --- ibuprofen --- manometry --- gastrointestinal --- mechanistic modeling --- PBPK --- PBBM --- disintegration --- dissolution --- enteric-coated --- ICH --- quality control --- regional intestinal permeability --- permeation enhancers --- absorption-modifying excipients --- oral peptide delivery --- intestinal perfusion --- pharmaceutical development --- controlled release drug product --- biopharmaceutics classification system --- drug solubility --- drug permeability --- location-dependent absorption --- segregated flow intestinal model (SFM) --- traditional model (TM) --- route-dependent intestinal metabolism --- first-pass effect --- drug-drug interactions --- DDI --- in vitro in vivo extrapolations --- IVIVE --- zero-order absorption --- first-order absorption --- combined zero- and first-order absorption --- transit compartment absorption model --- in situ perfusion --- microdevices --- shape --- mucoadhesion --- colon absorption --- nutrient digestion --- nutrient absorption --- gastrointestinal hormone --- postprandial glycaemia --- energy intake --- region of the gut --- obesity --- type 2 diabetes --- Franz–PAMPA --- BCS drugs --- biomimetic membrane --- Franz cell --- passive drug transport --- BCS class IV drugs --- segmental-dependent intestinal permeability --- intestinal absorption --- oral drug delivery --- biopharmaceutics --- physiologically-based pharmacokinetic (PBPK) modeling --- furosemide --- intestinal permeability --- human colon carcinoma cell layer (Caco-2) --- hierarchical support vector regression (HSVR) --- drug absorption --- drug solubility/dissolution --- regional/segmental-dependent permeability and absorption --- bioequivalence --- Biopharmaceutics Classification System --- in vitro --- dissolution test --- pravastatin --- oral absorption --- in silico modeling --- GastroPlus --- Phoenix WinNonlin --- pharmacokinetics --- clinical studies --- ibuprofen --- manometry --- gastrointestinal --- mechanistic modeling --- PBPK --- PBBM --- disintegration --- dissolution --- enteric-coated --- ICH --- quality control --- regional intestinal permeability --- permeation enhancers --- absorption-modifying excipients --- oral peptide delivery --- intestinal perfusion --- pharmaceutical development --- controlled release drug product --- biopharmaceutics classification system --- drug solubility --- drug permeability --- location-dependent absorption --- segregated flow intestinal model (SFM) --- traditional model (TM) --- route-dependent intestinal metabolism --- first-pass effect --- drug-drug interactions --- DDI --- in vitro in vivo extrapolations --- IVIVE --- zero-order absorption --- first-order absorption --- combined zero- and first-order absorption --- transit compartment absorption model --- in situ perfusion --- microdevices --- shape --- mucoadhesion --- colon absorption --- nutrient digestion --- nutrient absorption --- gastrointestinal hormone --- postprandial glycaemia --- energy intake --- region of the gut --- obesity --- type 2 diabetes --- Franz–PAMPA --- BCS drugs --- biomimetic membrane --- Franz cell --- passive drug transport --- BCS class IV drugs --- segmental-dependent intestinal permeability --- intestinal absorption --- oral drug delivery --- biopharmaceutics --- physiologically-based pharmacokinetic (PBPK) modeling --- furosemide --- intestinal permeability --- human colon carcinoma cell layer (Caco-2) --- hierarchical support vector regression (HSVR) --- drug absorption --- drug solubility/dissolution --- regional/segmental-dependent permeability and absorption
Choose an application
The gastrointestinal tract (GIT) can be broadly divided into several regions: the stomach, the small intestine (which is subdivided to duodenum, jejunum, and ileum), and the colon. The conditions and environment in each of these segments, and even within the segment, are dependent on many factors, e.g., the surrounding pH, fluid composition, transporters expression, metabolic enzymes activity, tight junction resistance, different morphology along the GIT, variable intestinal mucosal cell differentiation, changes in drug concentration (in cases of carrier-mediated transport), thickness and types of mucus, and resident microflora. Each of these variables, alone or in combination with others, can fundamentally alter the solubility/dissolution, the intestinal permeability, and the overall absorption of various drugs. This is the underlying mechanistic basis of regional-dependent intestinal drug absorption, which has led to many attempts to deliver drugs to specific regions throughout the GIT, aiming to optimize drug absorption, bioavailability, pharmacokinetics, and/or pharmacodynamics. In the book "Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation" we aim to highlight the current progress and to provide an overview of the latest developments in the field of regional-dependent intestinal drug absorption and delivery, as well as pointing out the unmet needs of the field.
Medicine --- Pharmaceutical industries --- bioequivalence --- Biopharmaceutics Classification System --- in vitro --- dissolution test --- pravastatin --- oral absorption --- in silico modeling --- GastroPlus --- Phoenix WinNonlin --- pharmacokinetics --- clinical studies --- ibuprofen --- manometry --- gastrointestinal --- mechanistic modeling --- PBPK --- PBBM --- disintegration --- dissolution --- enteric-coated --- ICH --- quality control --- regional intestinal permeability --- permeation enhancers --- absorption-modifying excipients --- oral peptide delivery --- intestinal perfusion --- pharmaceutical development --- controlled release drug product --- biopharmaceutics classification system --- drug solubility --- drug permeability --- location-dependent absorption --- segregated flow intestinal model (SFM) --- traditional model (TM) --- route-dependent intestinal metabolism --- first-pass effect --- drug-drug interactions --- DDI --- in vitro in vivo extrapolations --- IVIVE --- zero-order absorption --- first-order absorption --- combined zero- and first-order absorption --- transit compartment absorption model --- in situ perfusion --- microdevices --- shape --- mucoadhesion --- colon absorption --- nutrient digestion --- nutrient absorption --- gastrointestinal hormone --- postprandial glycaemia --- energy intake --- region of the gut --- obesity --- type 2 diabetes --- Franz–PAMPA --- BCS drugs --- biomimetic membrane --- Franz cell --- passive drug transport --- BCS class IV drugs --- segmental-dependent intestinal permeability --- intestinal absorption --- oral drug delivery --- biopharmaceutics --- physiologically-based pharmacokinetic (PBPK) modeling --- furosemide --- intestinal permeability --- human colon carcinoma cell layer (Caco-2) --- hierarchical support vector regression (HSVR) --- drug absorption --- drug solubility/dissolution --- regional/segmental-dependent permeability and absorption
Choose an application
The gastrointestinal tract (GIT) can be broadly divided into several regions: the stomach, the small intestine (which is subdivided to duodenum, jejunum, and ileum), and the colon. The conditions and environment in each of these segments, and even within the segment, are dependent on many factors, e.g., the surrounding pH, fluid composition, transporters expression, metabolic enzymes activity, tight junction resistance, different morphology along the GIT, variable intestinal mucosal cell differentiation, changes in drug concentration (in cases of carrier-mediated transport), thickness and types of mucus, and resident microflora. Each of these variables, alone or in combination with others, can fundamentally alter the solubility/dissolution, the intestinal permeability, and the overall absorption of various drugs. This is the underlying mechanistic basis of regional-dependent intestinal drug absorption, which has led to many attempts to deliver drugs to specific regions throughout the GIT, aiming to optimize drug absorption, bioavailability, pharmacokinetics, and/or pharmacodynamics. In the book "Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation" we aim to highlight the current progress and to provide an overview of the latest developments in the field of regional-dependent intestinal drug absorption and delivery, as well as pointing out the unmet needs of the field.
bioequivalence --- Biopharmaceutics Classification System --- in vitro --- dissolution test --- pravastatin --- oral absorption --- in silico modeling --- GastroPlus --- Phoenix WinNonlin --- pharmacokinetics --- clinical studies --- ibuprofen --- manometry --- gastrointestinal --- mechanistic modeling --- PBPK --- PBBM --- disintegration --- dissolution --- enteric-coated --- ICH --- quality control --- regional intestinal permeability --- permeation enhancers --- absorption-modifying excipients --- oral peptide delivery --- intestinal perfusion --- pharmaceutical development --- controlled release drug product --- biopharmaceutics classification system --- drug solubility --- drug permeability --- location-dependent absorption --- segregated flow intestinal model (SFM) --- traditional model (TM) --- route-dependent intestinal metabolism --- first-pass effect --- drug-drug interactions --- DDI --- in vitro in vivo extrapolations --- IVIVE --- zero-order absorption --- first-order absorption --- combined zero- and first-order absorption --- transit compartment absorption model --- in situ perfusion --- microdevices --- shape --- mucoadhesion --- colon absorption --- nutrient digestion --- nutrient absorption --- gastrointestinal hormone --- postprandial glycaemia --- energy intake --- region of the gut --- obesity --- type 2 diabetes --- Franz–PAMPA --- BCS drugs --- biomimetic membrane --- Franz cell --- passive drug transport --- BCS class IV drugs --- segmental-dependent intestinal permeability --- intestinal absorption --- oral drug delivery --- biopharmaceutics --- physiologically-based pharmacokinetic (PBPK) modeling --- furosemide --- intestinal permeability --- human colon carcinoma cell layer (Caco-2) --- hierarchical support vector regression (HSVR) --- drug absorption --- drug solubility/dissolution --- regional/segmental-dependent permeability and absorption
Listing 1 - 8 of 8 |
Sort by
|